E-DRUG: Access more affordable Valganciclovir through the Medicines Patent Pool
------------------------------------------------------------------------------------
Dear Colleagues,
On 5 August 2013, the Medicines Patent Pool and Swiss pharmaceutical company Roche signed an agreement to increase access to valganciclovir, an easy-to-take oral medicine to treat cytomegalovirus (CMV). CMV is a viral infection that if untreated can cause blindness in people living with HIV. The first phase of the MPP/Roche agreement includes a price reduction on on valganciclovir that makes it up to 90% cheaper than current market prices, for use in 138 developing countries.
Non-profit treatment organisations can now access valganciclovir at this price. Full instructions for ordering valganciclovir are available here:
http://www.medicinespatentpool.org/licensing/current-licences/access-more-affordable-valganciclovir-through-the-medicines-patent-pool-roche-agreement/
Thank you,
Kaitlin
Kaitlin Mara
Medicines Patent Pool
Kaitlin Mara <kmara@medicinespatentpool.org>